Activity of the new fluoroquinolone trovafloxacin (CP-99,219) against DNA gyrase and topoisomerase IV mutants of Streptococcus pneumoniae selected in vitro

Antimicrobial Agents and Chemotherapy

Volumn 40, Issue 12, 1996, Pages 2691-2697

  Gootz, Thomas D ^a   Zaniewski, Richard ^a   Haskell, Suzanne ^a   Schmieder, Brenda ^a   Tankovic, Jacques ^b   Girard, Dennis ^a   Courvalin, Patrice ^b   Polzer, Robert J ^a  

^a PFIZER INC   (United States)

^b INSTITUT PASTEUR   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; DNA TOPOISOMERASE (ATP HYDROLYSING); OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPARFLOXACIN; TROVAFLOXACIN;

AMINO ACID SUBSTITUTION; ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BACTERIUM ISOLATION; CONTROLLED STUDY; DRUG MECHANISM; ENZYME INHIBITION; GENE MUTATION; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; STREPTOCOCCUS PNEUMONIAE;

EID: 0029834825     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.40.12.2691     Document Type: Article

References (28)

1. Appelbaum, P. C. 1992. Antimicrobial resistance to Streptococcus pneumoniae: an overview. Clin. Infect. Dis. 15:77-83.
2. Baquero, F. 1995. Pneumococcal resistance to beta-lactam antibiotics: a global geographic overview. Microb. Drug Resist. 1:115-120.
3. Brown, S. D., A. L. Barry, and P. C. Fuchs. 1995. Spontaneously occurring staphylococcal mutants resistant to clinically achievable concentrations of ciprofloxacin and CP-99,219, a new fluoroquinolone, abstr. F235, p. 154. In Program and abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
4. Canton, E., J. Peman, M. T. Jimenez, M. S. Ramon, and M. Gobernado. 1992. In vitro activity of sparfloxacin compared with those of five other quinolones. Antimicrob. Agents Chemother. 36:558-565.
5. Child, J., J. Andrews, F. Boswell, N. Brenwald, and R. Wise. 1995. The in vitro activity of CP-99,219, a new naphthyridone antimicrobial agent: a comparison with fluoroquinolone agents. J. Antimicrob. Chemother. 35:869-876.
6. Ferrero, L., B. Cameron, and J. Crouzet. 1995. Analysis of gyrA and grlA mutations in stepwise-selected ciprofloxacin-resistant mutants of Staphylococcus aureus. Antimicrob. Agents Chemother. 39:1554-1558.
7. Ferrero, L., B. Cameron, B. Manse, D. Lagneaux, J. Crouzet, A. Famechon, and F. Blanche. 1994. Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: a primary target of fluoroquinolones. Mol. Microbiol. 13:641-653.
8. Girard, A. E., C. R. Cimochowski, S. M. Finegan, and T. D. Gootz. 1996. Trovafloxacin: efficacy vs. Streptococcus pneumoniae Topo IV mutants and lack of in vivo emergence of resistance, abstr. C116, p. 55. In Program and abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
9. Girard, A. E., D. Girard, T. D. Gootz, J. A. Faiella, and C. R. Cimochowski. 1995. In vivo efficacy of trovafloxacin (CP-99,219), a new quinolone with extended activities against gram-positive pathogens. Streptococcus pneumoniae and Bacteroides fragilis. Antimicrob. Agents Chemother. 39:2210-2216.
10. Gootz, T. D., and P. R. McGuirk. 1994. New quinolones in development. Expert. Opin. Invest. Drugs 3:93-114.
11. Hooper, D. C. 1995. Quinolone mode of action. Drugs 49(Suppl. 2):10-15.
12. Hori, S., Y. Ohshita, Y. Utsui, and K. Hiramatsu. 1993. Sequential acquisition of norfloxacin and ofloxacin resistance by methicillin-resistant and -susceptible Staphylococcus aureus. Antimicrob. Agents Chemother. 37:2278-2284.
13. Hoshino, K., A. Kitamura, I. Morrissey, K. Sato, J.-I. Kato, and H. Ikeda. 1994. Comparison of inhibition of Escherichia coli topoisomerase IV by quinolones with DNA gyrase inhibition. Antimicrob. Agents Chemother. 38:2623-2627.
14. Kaatz, G. W., S. M. Seo, and C. A. Ruble. 1991. Mechanisms of fluoroquinolone resistance in Staphylococcus aureus. J. Infect. Dis. 163:1080-1086.
15. Khodursky, A. B., E. L. Zechiedrich, and N. R. Cozzarelli. 1995. Topoisomerase IV is a target of quinolones in Escherichia coli. Proc. Natl. Acad. Sci. USA 92:11801-11805.
16. Klugman, K. P., and T. D. Gootz. Susceptibility of the drug resistant pneumococcus to trovafloxacin. J. Antimicrob. Chemother. (Suppl.), in press.
17. Mann, H. J., P. B. Bitterman, A. C. Anderson, R. Teng, A. Johnson, M. Avery, and J. Vincent. 1995. CP-99,219 penetration into human bronchial tissues and fluids following the administration of a single dose, abstr. F241, p. 155. In Program and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
18. Margerrisson, F. E., C. R. Hopewell, and L. M. Fisher. 1992. Nucleotide sequence of the Staphylococcus aureus gyrB-gyrA locus encoding the DNA gyrase A and B proteins. J. Bacteriol. 174:1596-1603.
19. Nau, R., T. Schmidt, K. Kaye, J. L. Froula, and M. G. Tauber. 1995. Quinolone antibiotics in therapy of experimental pneumococcal meningitis in rabbits. Antimicrob. Agents Chemother. 39:593-597.
20. Neiderman, M. Comparison of trovafloxacin once daily and cefaclor three times daily in patients with acute community-acquired pneumonia. J. Antimicrob. Chemother. (Suppl.), in press.
21. Peng, H., and K. J. Marians. 1993. Escherichia coli topoisomerase IV: purification, characterization, and subunit structure, and subunit interactions. J. Biol. Chem. 268:24481-24490.
22. Scully, B. E. 1993. Therapy of respiratory tract infections with quinolone antimicrobial agents, p. 339-362. In D. C. Hooper and J. S. Wolfson (ed.), Quinolone antimicrobial agents, 2nd ed. American Society for Microbiology, Washington, D.C.
23. Spangler, S. K., M. R. Jacobs, and P. C. Appelbaum. 1994. Activity of CP-99,219 compared with those of ciprofloxacin, grepafloxacin, metronidazole, cefoxitin, piperacillin, and piperacillin-tazobactam against 489 anaerobes. Antimicrob. Agents Chemother. 38:2471-2476.
24. Tankovic, J., B. Perichon, J. Duval, and P. Courvalin. 1996. Contribution of mutations in the gyrA and parC genes to fluoroquinolone resistance of mutants of Streptococcus pneumoniae obtained in vivo and in vitro. Antimicrob. Agents Chemother. 40:2505-2510.
25. Teng, R., D. R. Brennan, T. G. Tensfeldt, T. E. Liston, and G. Foulds. 1996. Determination of CP-99,219, a new oral quinolone antibiotic, in biological samples by reverse-phase high pressure liquid chromatography. J. Chromatogr. B: Biomed. Appl. 675:53-59.
26. Teng, R., S. C. Harris, D. E. Nix, J. J. Schentag, G. Foulds, and T. E. Liston. 1995. Pharmacokinetics and safety of trovafloxacin (CP-99,219), a new quinolone antibiotic, following administration of single oral doses to healthy male volunteers. J. Antimicrob. Chemother. 36:385-394.
27. Visalli, M. A., M. R. Jacobs, and P. C. Appelbaum. 1996. Activity of CP-99,219 (trovafloxacin) compared with ciprofloxacin, sparfloxacin, clinafloxacin, lomefloxacin, and cefuroxime against ten penicillin-susceptible and penicillin-resistant pneumococci by time-kill methodology. J. Antimicrob. Chemother. 37:77-84.
28. Yoshida, H., M. Bogaki, S. Nakamura, K. Ubukata, and M. Konno. 1990. Nucleotide sequence and characterization of the Staphylococcus aureus norA gene, which confers resistance to quinolones. J. Bacteriol. 172:6942-6949.